You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1627 Results
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Jul 2023
Regimen
Cancer Type:
Hematologic, 
Myelodysplastic Syndrome (MDS)
Intent: Palliative
Funding:
Exceptional Access Program
    decitabine / cedazuridine - For the treatment of adult patients with myelodysplastic syndromes (MDS), according to clinical criteria
Feb 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Avelumab - Maintenance Treatment for Unresectable Locally Advanced or Metastatic Urothelial Carcinoma
Jan 2025
Regimen
Cancer Type:
Gynecologic, 
Cervix, 
Endometrial, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
Dec 2024
Regimen
Cancer Type:
Gynecologic, 
Endometrial, 
Ovary
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
Dec 2024
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Adjuvant, Curative
Feb 2021

Pages